SN
Suhas Narayan Sakalkar
About Suhas Narayan Sakalkar
Data last updated:
Suhas Narayan Sakalkar has 6 years in corporate governance. Holds Director and Designated Partner roles. Currently with 2 companies, including Chemotech Industries India Private Limited and Acquaint Life Sciences Llp. Formerly with 1 company, such as Svgpharma Lifesciences Private Limited. Engaged in Technology, General Business. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
 Chemotech Industries India Private Limited U24290MH2020PTC346978 | Director | 30 Sep 2020 | 2020 | Active |
| Acquaint Life Sciences Llp ACG-0256 | Designated Partner | 12 Mar 2024 | 2024 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
| Svgpharma Lifesciences Private Limited U24290MH2020PTC346345 | Director | 12 Apr 2021 | 2020 | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Suhas Narayan Sakalkar
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Suhas Narayan Sakalkar
Suhas Narayan Sakalkar has 6 years in corporate governance. Holds Director and Designated Partner roles. Currently with 2 companies, including Chemotech Industries India Private Limited and Acquaint Life Sciences Llp. Formerly with 1 company, such as Svgpharma Lifesciences Private Limited. Engaged in Technology, General Business. Contributes to corporate operations.
Suhas Narayan Sakalkar is associated with 2 companies as Director and Designated Partner.
Suhas Narayan Sakalkar has expertise in Technology, General Business.
Suhas Narayan Sakalkar has 6 years in corporate governance.